IDYA6:00 AMIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)ideayabio.com
IDYA6:00 AMIDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directorsideayabio.com
IDYA6:00 AMIDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung CancersTrial Start • Phase 1Trial initiation Mon, Jun 15, 2026ideayabio.com
IDYA4:05 PMIDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Sharesideayabio.com
IDYA10:22 PMIDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrantsideayabio.com
IDYA4:01 PMIDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrantsideayabio.com
IDYA6:00 AMIDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic CancerTrial Start • Phase 1ideayabio.com
IDYA11:00 AMIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCOPresentation / Abstract • Phase 2/3Late-breaking oral presentation at ASCO Mon, Jun 1, 2026ideayabio.com
IDYA6:00 AMIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)ideayabio.com
IDYA6:00 AMIDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conferenceideayabio.com
IDYA6:00 AMIDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateTrial Results • Phase 2/3ideayabio.com
IDYA6:00 AMIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)ideayabio.com
IDYA6:00 AMIDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) ProgramTrial Results • Phase 2/3ideayabio.com
IDYA10:15 AMIDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal MelanomaPresentation / Abstract • Phase 2/3ideayabio.com